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TO THE EDITOR
Merkel cell carcinoma (MCC) is an
increasingly common neuroendocrine
cancer of the skin. MCC is an aggres-
sive malignancy that is a significant
cause of nonmelanoma skin cancer
deaths. Although the genetics of MCC
are poorly characterized, it is well
established that MCC is associated with
advanced age and UV exposure. MCC
is also linked to immune suppression;
8% of MCC patients are chronically
immunosuppressed, which is a 16-fold
overrepresentation (Heath et al., 2008).
In particular, MCC is linked to T-cell
dysfunction associated with malignant,
infectious, and iatrogenic causes (Miller
and Rabkin, 1999; Engels et al., 2002;
Heath et al., 2008).
Recently, Feng et al. (2008), de-
scribed a novel polyomavirus that is
associated with MCC. This virus,
named Merkel cell polyomavirus
(MCPyV), was present in 8 of 10 MCC
tumors as compared to 1 of 15 normal
skin controls. Several clues suggest a
possible functional role for this virus in
cancer. MCPyV shares key features with
the SV40 polyomavirus, an oncogenic
virus in animals, such as the predicted
ability of a viral T antigen protein to
bind and inactivate the tumor suppres-
sor Rb. Furthermore, MCPyV DNA was
reported to be monoclonally integrated
into six of the tumors, which implies
that viral integration was an early event
in MCC carcinogenesis and occurred
before tumor expansion.
See related commentary on pg 9
Abbreviations: MCC, Merkel cell carcinoma; MCPyV, Merkel cell polyomavirus
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To confirm this recent discovery, we
used quantitative real-time PCR to
detect the presence or absence of
MCPyV DNA in 37 MCC tumor speci-
mens originating from 37 patients in
North America and Australia. Two
primer sets targeting MCPyV, but not
other known human polyomaviruses,
were used. One set amplifies the region
corresponding to the common portion
of large and small T antigen (nucleo-
tides 236–374 of the ‘‘MCV350’’ se-
quence (EU375803)) and the second
set amplifies a portion of the large
T antigen surrounding a BamH1 restric-
tion site (nucleotides 1083–1181). Pro-
ducts of the second set were digested
with BamH1 and resolved on an
acrylamide gel to verify product speci-
ficity. For a comparison control gene,
primers were designed to amplify a
gene on chromosome 2 (the TPO gene)
because chromosome 2 is usually
stable and only rarely gained or lost in
MCC tumors (Van Gele et al., 1998).
Serial dilutions were employed to
calibrate the relative efficiency of the
PCR reactions and ensure that the DDCT
method could be used to determine
relative amounts of DNA between
the viral and control genomic targets.
The sensitivity of the real-time platform
allowed us to detect levels of the
viral gene as low as 1/5,000th the
level of the control gene. All reactions
were carried out in triplicate, and
water and pooled human male
lymphocyte DNA were included as
negative controls. We also performed
the PCR under less stringent conditions
(lower annealing temperature). Under
these conditions, we did not detect
additional MCPyV-positive tumors,
but cannot rule out the possibility of
presence of a strain variant in the
negative tumors.
We found that 16 of 37 MCC tumor
tissues were positive for MCPyV DNA
(43%). Interestingly, the proportion of
tumors positive for MCPyV was much
higher in tumors originating from North
America than those originating from
Australia (Figure 1). Among North
American MCC specimens, 11 of 16
tumors (69%) were positive, which is
similar to the initial report of 8 of 10
tumors (Feng et al., 2008). In contrast,
only 5 of 21 Australian MCC specimens
(24%) were positive for MCPyV. In
addition, we tested 15 primary squa-
mous-cell carcinoma tumors, and 15
apparently normal sun-exposed skin
samples, from 30 North American
patients without MCC. These patients
had a similar age and gender distribu-
tion to the MCC patients. MCPyV was
not detected in any of the normal skin
DNA, but was present in 2 of 15
squamous-cell carcinoma tumors (13%).
The MCC tumor tissues tested in-
cluded primaries and metastases. We
observed MCPyV in 5 of 8 primary
tumors, 3 of 13 recurrences, 7 of 15
nodal metastases, and in the single-
studied distant metastasis. Outcome
data were available for 30 of the 37
patients. In this subset, no survival
difference was noted between virus-
positive and virus-negative tumors
using Kaplan–Meier analysis (data not
shown). We found wide variation in the
amount of viral DNA present. Indeed,
the amount of viral DNA relative to
control DNA varied over five orders of
magnitude among the virus-positive
MCC tumors (Figure 2).
These data confirm the important
discovery of Feng et al., that a poly-
omavirus is associated with MCC. Virus
was present in MCC tumors, and was
present in a similar percentage of
North American tumors as previously
reported.
Our data further present the interest-
ing observation that North American
MCC tumors are more frequently
MCPyV positive than Australian MCC
tumors. This difference may be due to
the increased sun exposure in Australia,
making a possible viral contribution less
frequent. We cannot exclude the possi-
bility that a different and unknown
MCPyV strain, not detectable with our
specific assay, or perhaps an alternate
virus is present in the Australian MCCs.
The majority of Australian samples were
nodal metastases, whereas most North
American samples were primaries. How-
ever, we believe this is unlikely to
account for the observed difference in
viral prevalence because in two cases
we had both primary and nodal tissues
and all tissues were virus positive (data
not shown). It is important to note that
most of the Australian tumor specimens
were collected in the 1990s and most
North American specimens were col-
lected after the year 2000. However,
DNA quality from the Australian speci-
mens was excellent both by spectro-
photometry and PCR of control genes.
Our observed percentages may over- or
under-represent the true prevalence of
MCPyV in MCC tumors because our left
over surgical specimens are biased
toward more advanced MCC than aver-
age. This was true of both the Australian
and North American specimens.
Of 15 squamous-cell carcinoma sam-
ples 2 had detectable MCPyV DNA. A
larger study is required to determine
whether MCPyV is reproducibly more
often present in squamous-cell carcino-
ma tumors than in normal skin.
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Figure 1. Prevalence of MCPyV DNA in samples from North America (NA) and Australia (AU).
Quantitative PCR was carried out targeting the T antigen region of the MCPyV genome. MCC, Merkel cell
carcinoma; SCC, squamous-cell carcinoma; skin, UV-exposed skin from age- and sex-matched controls.
P-values calculated using Fisher’s exact test.
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MCPyV represents an exciting direc-
tion for future studies in two major
areas. The first area is functional
characterization of the MCPyV and
determination if it expresses biologi-
cally active viral proteins and whether
it is in fact involved in the generation or
maintenance of MCC tumors. The
second major direction is an epidemio-
logic characterization of the prevalence
of MCPyV in healthy people and in
various tumors as this virus may plau-
sibly be associated with other human
diseases or malignancies.
Merkel cell carcinoma specimens
were from the ‘‘Repository of Data
and Specimens for Merkel Cell
Carcinoma Research’’ at the Fred
Hutchinson Cancer Research Center.
Normal sun-exposed skin and
squamous-cell carcinoma tumors were
from the ‘‘Main Biomarker Research
Specimen Repository’’ at the University
of Washington. The relevant
Institutional Review Boards approved
this study, and this study was
performed with strict adherence
to the Declaration of Helsinki
Principles.
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TO THE EDITOR
Merkel cell carcinoma (MCC) is a rare,
but highly aggressive neuroendocrine
cancer of the skin that occurs primarily
in elderly immune-suppressed indivi-
duals. Little is known about the patho-
genesis of MCC. Now Feng et al. (2008)
have identified a new polyomavirus
present in MCC (MCPyV). In this
regard, viral proteins expressed by
polyomaviruses are known to initiate
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Figure 2. Marked variability of Merkel cell polyomavirus DNA quantity among MCC tumors. The
amount of MCPyV DNA was compared to the amount of DNA of a control gene on chromosome 2 (TPO).
Note the wide range in levels of MCPyV DNA. MCC primaries (n¼ 8, circles), recurrences (n¼ 13,
squares), nodal metastases (n¼ 15, triangles), and distant metastases (n¼1, diamond) are compared. Also
shown are squamous-cell carcinomas (ovals) and sun-exposed skin controls (pentagons). Tumors
originating from North America are represented with closed symbols and those originating from Australia
are represented with open symbols. Tumors represented as not detected had good amplification of
control gene but no detectable MCPyV by both primer sets.
See related commentary on pg 9
Abbreviations: MCC, Merkel cell carcinoma; MCPyV, Merkel cell polyomavirus
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